Status:

TERMINATED

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

Lead Sponsor:

Vanderbilt-Ingram Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to c...

Detailed Description

OBJECTIVES: * Determine cyclooxygenase-2 (COX-2) over-expression in tumor specimens from patients with early-stage rectal cancer. * Determine whether administration of a COX-2 inhibitor, celecoxib, r...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Clinical diagnosis of primary adenocarcinoma of the rectum (to be histologically confirmed upon study entry)
  • Tumor must be at or below the peritoneal reflection
  • The distal border of the tumor is within 12 cm of the anal verge on proctoscopic examination
  • Clinically resectable disease
  • PATIENT CHARACTERISTICS:
  • Karnofsky performance status 60-100%
  • WBC ≥ 4,000/mm³
  • Platelet count ≥ 150,000/mm³
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other serious medical illness (other than rectal cancer) that would preclude study therapy
  • No psychiatric condition that would preclude informed consent
  • No history of allergy to celecoxib or any other NSAIDs, including acetylsalicylic acid (i.e., aspirin), ibuprofen, or indomethacin
  • No history of allergy to sulfonamides
  • Exclusion criteria:
  • Not noted
  • PRIOR CONCURRENT THERAPY:
  • At least 7 days since prior and no concurrent NSAIDs or other cyclooxygenase-2 inhibitors
  • No concurrent warfarin, except low-dose warfarin (i.e., 1 mg/day) administered for prophylaxis

Exclusion

    Key Trial Info

    Start Date :

    July 1 2002

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2008

    Estimated Enrollment :

    10 Patients enrolled

    Trial Details

    Trial ID

    NCT00608595

    Start Date

    July 1 2002

    End Date

    April 1 2008

    Last Update

    March 5 2013

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Veterans Administration

    Nashville, Tennessee, United States, 37212

    2

    Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, United States, 37232